Evidence map›Paper›PMID 31231400›Full record

ReviewFrontiers in immunology2019

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Ziduo Li, Xinsheng Ju, Pablo A Silveira, Edward Abadir, Wei-Hsun Hsu, Derek N J Hart, Georgina J Clark

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. γδ T cells show distinct responses to CMV after stem cell transplantation.Journal of molecular medicine (Berlin, Germany) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Mature CD209Scientific reports · 2025
    Article
  18. Article
  19. Article
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ziduo LiDendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.
Xinsheng JuDendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.
Pablo A SilveiraDendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.
Edward AbadirDendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.
Wei-Hsun HsuDendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.
Derek N J HartDendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.
Georgina J ClarkDendritic Cell Research, ANZAC Research Institute, Sydney, NSW, Australia.
University of Sydney · AUAnzac Research Institute · AU

Funding

Medical Research Council
6 · The paper itself

Abstract

CD83 is a member of the immunoglobulin (Ig) superfamily and is expressed in membrane bound or soluble forms. Membrane CD83 (mCD83) can be detected on a variety of activated immune cells, although it is most highly and stably expressed by mature dendritic cells (DC). mCD83 regulates maturation, activation and homeostasis. Soluble CD83 (sCD83), which is elevated in the serum of patients with autoimmune disease and some hematological malignancies is reported to have an immune suppressive function. While CD83 is emerging as a promising immune modulator with therapeutic potential, some important aspects such as its ligand/s, intracellular signaling pathways and modulators of its expression are unclear. In this review we discuss the recent biological findings and the potential clinical value of CD83 based therapeutics in various conditions including autoimmune disease, graft-vs.-host disease, transplantation and hematological malignancies.

Indexed as

AnimalsAntigen-Presenting CellsAntigens, CDCD83 AntigenHumansImmunoglobulinsMembrane GlycoproteinsAntigens, CDCD83 AntigenImmunoglobulinsMembrane Glycoproteinsantigen presenting cellsCD83immune suppressiontherapeutic antibodytransplantation

Identifiers

PMID31231400
PMCPMC6568190
OpenAlexW2971798665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.